A clinical study designed to test a higher dose of intravitreal ranibizumab (Lucentis) on neovascular age-related macular degeneration (AMD) patients with persistent disease activity has reported statistically significant visual acuity (VA) gains. The study, led by the SAVE [Super-dose Anti-VEGF] Study Group had hypothesized that a higher dose (2.0 mg versus the approved 0.5 mg) may show improved efficacy based on the original dose dependent findings of the published MARINA and ANCHOR clinical trials. The 3-month SAVE data will need to be followed out to 24 months to determine whether or not the initial gains are sustained.
Super dose Lucentis study reports visual acuity gains and anatomic improvements
- by swdadmin